Related Experiment Video
Updated: Aug 17, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary
Kristina Bacher Svendsen1, Troels Staehelin Jensen, Flemming W Bach
1Dansk Smerteforskningscenter, Neurologisk Afdeling F, Arhus Universitetshospital, Arhus Sygehus. kristina@akhphd.au.dk
Abstract:
Cannabinoids reduce allodynia/hyperalgesia in animal pain models, but few clinical studies evaluated the analgesic action in humans. We aimed to evaluate the effect of delta-9-tetrahydrocannabinol (dronabinol) on central pain in MS patients. Twenty-four MS patients participated in a double-blind placebo-controlled crossover trial. Dronabinol reduced the spontaneous pain intensity significantly compared with placebo (4.0 (2.3-6.0) vs. 5.0 (4.0-6.4), median (25th-75th percentiles), p = 0.02). Though dronabinol's analgesic effect is modest, its use should be evaluated considering the general difficulty in treating central pain.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
